NCT06107582 Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
| NCT ID | NCT06107582 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | Primary Immune Thrombocytopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-11-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Immune thrombocytopenic purpura (ITP) is a kind of rare childhood disease that involve autoimmune destruction of platelets.The current Pediatric ITP cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in pediatric ITP. The purpose of this study is to analyze the clinical characteristics of Pediatric ITP, the treatment methods, prognosis and prognostic model of these patients in China.
Eligibility Criteria
Inclusion Criteria: * Age 6-17 years old (including both ends), male and female; * Diagnosis of ITP. Exclusion Criteria: * Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.; * The expected follow-up period is less than 3 months.
Contact & Investigator
Lei Zhang, MD
PRINCIPAL INVESTIGATOR
Chinese Academy of Medical Science and Blood Disease Hospital
Frequently Asked Questions
Who can join the NCT06107582 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Primary Immune Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06107582 currently recruiting?
Yes, NCT06107582 is actively recruiting participants. Contact the research team at sunting@ihcams.ac.cn for enrollment information.
Where is the NCT06107582 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06107582 clinical trial?
NCT06107582 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The principal investigator is Lei Zhang, MD at Chinese Academy of Medical Science and Blood Disease Hospital. The trial plans to enroll 500 participants.